SCHEMBL4200476

SCHEMBL4200476

COc1cc(-c2cnn(-c3ccccc3)n2)ccc1-c1ccccn1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 2/20 0.48
GRM5 P41594 6/20 0.46
ALDH1A1 P00352 2/20 0.41
MAPT P10636 2/20 0.41
HPGDS O60760 1/20 0.41
GAA P10253 1/20 0.41
KDR P35968 1/20 0.41
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
DCTPP1 Q9H773 1/20 0.40
ADORA2A P29274 1/20 0.39
ADORA1 P30542 1/20 0.39
NTRK1 P04629 1/20 0.39
ERN1 O75460 1/20 0.39
SYK P43405 1/20 0.39
HPGD P15428 1/20 0.38
CREBBP Q92793 1/20 0.38
HSD17B10 Q99714 1/20 0.38
NPC1 O15118 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5470984 0.88 GRM5 (0.53) ATMGRM5KDRKDM4EMEN1
SCHEMBL29050578 0.78 GRM5 (0.53) ATMGRM5MAPTKDRKDM4E
SCHEMBL14668861 0.78 ERN1 (0.48) ATMGRM5ALDH1A1MAPTGAA
SCHEMBL28710992 0.76 SYK (0.50) ATMGRM5ALDH1A1MAPTKDM4E
SCHEMBL5833461 0.76 KDM4E (0.43) GRM5ALDH1A1MAPTKDRKDM4E
SCHEMBL8338124 0.74 HTT (0.48) ATMGRM5MEN1KMT2A
SCHEMBL5668689 0.73 GRM5 (0.50) ATMGRM5ALDH1A1MAPTGAA
Hydrochloric Acid SCHEMBL5315800 0.73 HTT (0.47) ATMGRM5MEN1KMT2A
SCHEMBL5479059 0.73 GUSB (0.42) ATMGRM5ALDH1A1MAPTGAA
SCHEMBL13683940 0.72 GRM5 (0.53) GRM5KDM4EMEN1KMT2ADCTPP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1613617-A4 DI-ARYL SUBSTITUTED TRIAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2009-02-18 EP disclosed
US-7268151-B2 Di-aryl substituted triazole modulators of metabotropic glutamate receptor-5 MERCK & CO., INC. (US) 2007-09-11 US disclosed
US-20070082067-A1 Di-aryl substituted triazole modulators of metabotropic glutamate receptor-5 MERCK SHARP & DOHME CORP. 2007-04-12 US disclosed
EP-1613617-A2 DI-ARYL SUBSTITUTED TRIAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 Merck & Co., Inc. (US) 2006-01-11 EP disclosed
WO-2004089306-A2 DI-ARYL SUBSTITUTED TRIAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO., INC. (US) 2004-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070082067-A1 Di-aryl substituted triazole modulators of metabotropic glutamate receptor-5 GRM5, GRM1, GRIA3 ATM 4142/4885GRM5 1/4885ALDH1A1 740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.